Mild cognitive impairment in patients with Parkinson's disease: An updated mini-review and future outlook

Rwei-Ling Yu1, Ruey-Meei Wu2

  • 1College of Medicine, Institute of Behavioral Medicine, National Cheng Kung University, Tainan, Taiwan.

Insights

Parkinson's disease patients often experience mild cognitive impairment (MCI), a precursor to dementia. This review examines diagnostic criteria and cognitive patterns in Parkinson's disease mild cognitive impairment (PD-MCI) to aid early detection and treatment.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is a common non-motor symptom in Parkinson's disease (PD).
  • MCI signifies a transitional stage between normal aging and dementia, acting as a dementia predictor.
  • Existing diagnostic criteria for PD-MCI lack consistency, hindering clinical application.

Purpose of the Study:

  • To review diagnostic criteria for Parkinson's disease with mild cognitive impairment (PD-MCI).
  • To focus on the heterogeneity of cognitive function and progression rates in PD-MCI patients.
  • To provide insights for clinical diagnosis, early intervention, and treatment strategies.

Main Methods:

  • Literature review of diagnostic criteria for PD-MCI.
  • Analysis of cognitive function patterns and progression in PD-MCI.
  • Discussion of unmet needs and future research directions in the field.

Main Results:

  • Parkinson's disease mild cognitive impairment (PD-MCI) presents diverse cognitive profiles.
  • Cognitive impairments in PD-MCI exhibit varied progression rates.
  • Inconsistent diagnostic criteria complicate the identification and management of PD-MCI.

Conclusions:

  • Standardized diagnostic criteria for PD-MCI are crucial for effective clinical management.
  • Understanding cognitive heterogeneity is key for personalized interventions in PD-MCI.
  • Further research is needed to address unmet needs and advance the field of PD-MCI.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
672
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
354
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248